Naptumomab estafenatox: Targeted immunotherapy with a novel immunotoxin topical collection on evolving therapies

Current Oncology Reports

Volumn 16, Issue 2, 2014, Pages

  Eisen, Tim ^a   Hedlund, Gunnar ^b   Forsberg, Göran ^b   Hawkins, Robert ^c,d  

^a St John's Innovation Centre   (United Kingdom)

^b Active Biotech Research AB   (Sweden)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

5T4 tumor antigen; Carcinoma; Evolving therapies; Immunotherapy; Immunotoxin; Kidney cancer; Naptumomab estafenatox; Renal cell carcinoma; Tumor targeted superantigen

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL MARKER; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; NAPTUMOMAB ESTAFENATOX; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; ENTEROTOXIN; MONOCLONAL ANTIBODY;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL EXPANSION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HUMAN; KIDNEY CARCINOMA; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTIC INFILTRATION; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL DESTRUCTION; CLINICAL TRIAL (TOPIC); DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NEOPLASM; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; ENTEROTOXINS; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; NEOPLASMS; SUPERANTIGENS; T-LYMPHOCYTES;

EID: 84899423143     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-013-0370-0     Document Type: Article

References (32)

1. Dohlsten M, Hedlund G, Akerblom E, Lando PA, Kalland T. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc Natl Acad Sci U S A. 1991;88:9287-91.
2. Dohlsten M, Abrahmsen L, Bjork P, Lando PA, Hedlund G, et al. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy. Proc Natl Acad Sci U S A. 1994;91:8945-9. This article describes the pre-clinical background for the Tumor Targeted Superantigen concept.
3. Dohlsten M, Hansson J, Ohlsson L, Litton M, Kalland T. Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Proc Natl Acad Sci U S A. 1995;92:9791-5.
4. Carlsson R, Fischer H, Sjogren HO. Binding of staphylococcal enterotoxin A to accessory cells is a requirement for its ability to activate human T cells. J Immunol. 1988;140:2484-8.
5. Fischer H, Dohlsten M, Lindvall M, Sjogren HO, Carlsson R. Binding of staphylococcal enterotoxin A to HLA-DR on B cell lines. J Immunol. 1989;142:3151-7.
6. Hedlund G, Dohlsten M, Lando PA, Kalland T. Staphylococcal enterotoxins direct and trigger CTL killing of autologous HLA-DR∈+∈mononuclear leukocytes and freshly prepared leukemia cells. Cell Immunol. 1990;129:426-34.
7. Hedlund G, Dohlsten M, Petersson C, Kalland T. Superantigen-based tumor therapy: in vivo activation of cytotoxic T cells. Cancer Immunol Immunother. 1993;36:89-93.
8. Dohlsten M, Lando PA, Hedlund G, Trowsdale J, Kalland T. Targeting of human cytotoxic T lymphocytes to MHC class II-expressing cells by staphylococcal enterotoxins. Immunology. 1990;71:96-100.
9. Dohlsten M, Hedlund G, Kalland T. Staphylococcal-enterotoxin-dependent cell-mediated cytotoxicity. Immunol Today. 1991;12:147-50.
10. Giantonio BJ, Alpaugh RK, Schultz J, McAleer C, Newton DW, et al. Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. J Clin Oncol. 1997;15:1994-2007.
11. Alpaugh RK, Schultz J, McAleer C, Giantonio BJ, Persson R, et al. Superantigen-targeted therapy: phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies. Clin Cancer Res. 1998;4:1903-14.
12. Forsberg G, Skartved NJ, Wallen-Ohman M, Nyhlen HC, Behm K, et al. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity. J Immunother. 2010;33:492-9. This article describes the molecular characteristics and preclinical efficacy studies of naptumomab estafenatox.
13. Hedlund G, Eriksson H, Sundstedt A, Forsberg G, Jakobsen BK, Pumphrey N, et al. The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity. PLoS One. 2013;8(10):e79082.
14. Forsberg G, Ohlsson L, Brodin T, Bjork P, Lando PA, et al. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br J Cancer. 2001;85:129-36.
15. Cheng JD, Babb JS, Langer C, Aamdal S, Robert F, et al. Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936. J Clin Oncol. 2004;22:602-9.
16. Shaw DM, Connolly NB, Patel PM, Kilany S, Hedlund G, et al. A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer. 2007;96:567-74. This article presents the results of the phase 2 study with the predecessor compound anatumomab mafenatox in RCC exploring early efficacy and IL-2 as a pharmacodynamic biomarker.
17. Hole N, Stern PL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer. 1988;57:239-46.
18. Hole N, Stern PL. Isolation and characterization of 5T4, a tumour-associated antigen. Int J Cancer. 1990;45:179-84.
19. Southgate TD, McGinn OJ, Castro FV, Rutkowski AJ, Al-Muftah M, et al. CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells. PLoS ONE. 2010;5:e9982.
20. Starzynska T, Marsh PJ, Schofield PF, Roberts SA, Myers KA, et al. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer. 1994;69:899-902.
21. Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley M, et al. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer. 1990;61:89-95.
22. Jones H, Roberts G, Hole N, McDicken IW, Stern P. Investigation of expression of 5T4 antigen in cervical cancer. Br J Cancer. 1990;61:96-100.
23. Naganuma H, Kono K, Mori Y, Takayoshi S, Stern PL, et al. Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer. Anticancer Res. 2002;22:1033-8.
24. Starzynska T, Rahi V, Stern PL. The expression of 5T4 antigen in colorectal and gastric carcinoma. Br J Cancer. 1992;66:867-9.
25. Starzynska T, Wiechowska-Kozlowska A, Marlicz K, Bromley M, Roberts SA, et al. 5T4 oncofetal antigen in gastric carcinoma and its clinical significance. Eur J Gastroenterol Hepatol. 1998;10:479-84.
26. Wrigley E, McGown AT, Rennison J, Swindell R, Crowther D, et al. 5T4 oncofetal antigen expression in ovarian carcinoma. Int J Gynecol Cancer. 1995;5:269-74.
27. Connor ME, Stern PL. Loss of MHC class-I expression in cervical carcinomas. Int J Cancer. 1990;46:1029-34.
28. Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, et al. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:4116-23. This article describes the phase 1 results comprising safety, early efficacy and pharmacodynamic responses with naptumomab estafentox in patients with RCC, NSCLC and pancreatic cancer.
29. Robinson MK, Alpaugh RK, Borghaei H. Naptumomab estafenatox: a new immunoconjugate. Expert Opin Biol Ther. 2010;10:273-9.
30. Sundstedt A, Celander M, Hedlund G. Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects. Int Immunopharmacol. 2008;8:442-52.
31. Hawkins RE, Gore ME, Shparyk Y, Bondar V, Gladkov O, Ganev T, et al. A randomized phase II/III study of naptumomab estafenatox plus IFN-α versus IFN-α in advanced renal cell carcinoma. J Clin Oncol. 2013;31(15 Suppl):3073.
32. Nirschl CJ, Drake CG. Molecular pathways: co-expression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res. 2013;19:4917-24. This article emphasizes the importance of controlling the immune checkpoints to achieve effective immune therapy, implicating a combinatory benefit with naptumomab estafenatox.